US Patent

US8460704 — Extended release formulation of nevirapine

Method of Use · Assigned to Boehringer Ingelheim International GmbH · Expires 2029-03-12 · 3y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects an extended release formulation of the pharmaceutical nevirapine.

USPTO Abstract

The invention relates to an extended release pharmaceutical composition comprising nevirapine.

Drugs covered by this patent

Viramune (NEVIRAPINE) · Boehringer Ingelheim

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1409`	—	Viramune

Patent Metadata

Patent number: US8460704
Jurisdiction: US
Classification: Method of Use
Expires: 2029-03-12
Drug substance claim: No
Drug product claim: No
Assignee: Boehringer Ingelheim International GmbH
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.